Avantor: Unloved Lab And Medical Testing Supplier Under Heavy Accumulation

  • Avantor is trading at its lowest valuation since 2019, attracting significant management buying of the stock, with clear chart accumulation trends since April. AVTR has been aggressively repaying debt, selling assets and restructuring operations, aiming for $400-500 million in annual savings by late 2026, especially if sales rebound. Risks include potential trade tariffs, U.S. healthcare research spending cuts, and recession, but insider votes of confidence (share buying) suggest a bullish outlook for new investment.